The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Software
  • Sports

Myonex Launches CTRx Europe, Central Pharmacy Network
The PennZone/10202189

Trending...
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • Mister Omaha Tries The Turf At Lone Star Park
HORSHAM, Pa.--(BUSINESS WIRE)--Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe. Built on a successful North American program, CTRx Europe offers significant benefits for trial sponsors, sites, and patients alike.

"With the growth of our CTRx service in North America, clients have been asking us to develop the same solution for them in Europe. Our new CTRx Europe solution is a game-changer for clinical sites in Europe," said James Lovett, Chief Executive Officer at Myonex. "Our solution will offer support for sites to source local drug for local patients, in individual European countries. Sponsors can remove overage and eliminate costs associated with up-front bulk comparator purchases, inventory management, and expired drugs. The program has delivered tremendous results in the United States and Canada, and we are pleased to be able to offer similar flexibility and savings in Europe."

More on The PennZone
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Morrisville & Cary Education Centers Honored with National Award
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park

Through its partnerships with central dispensing pharmacies in major European markets, Myonex can offer on-demand local sourcing. The CTRx solution provides sponsors with in-country local pricing and access to key oncology and other specialty medications and hospital lines. Sites need less storage space and fewer resources, so they can accommodate more trials. Sponsors can track dispensing via a secure, GDPR-compliant portal, and sites can request orders online.

Myonex's CTRx solution supports traditional, decentralized, and hybrid trials. In processes tailored to meet local regulations, both sponsor investigational medicinal products and commercial drugs, as well as ancillary items, can be delivered directly to the clinical site, central nursing center, a nurse, or even to the patient's home.

"The direct-to-patient offering makes adherence easier," said Samit Bhatt, Senior Director, Clinical Trial Patient Solutions, at Myonex. "And because our local partners serve local markets, logistics costs per patient and site shipment are lower, and sponsors can see significantly improved study start-up time."

More on The PennZone
  • Destination Niagara Launches Game Changing Digital Magazine Redefining How Visitors Experience Niagara Falls
  • Val Market is the New Frontier of the Online Marketplace
  • San Diego's newest marketing firm is boring on purpose — it's working
  • Arizona Christian Homeschools Launches Statewide Directory
  • LKPFM Corporation Canada the importance

CTRx Europe is part of an end-to-end suite of clinical trial supply solutions from Myonex that also includes expanded packaging and labeling capabilities; warehousing, storage, and distribution; project management and more. For information, email globalsales@myonex.com.

About Myonex
Myonex
is a leading global clinical trial supply company with more than 30 years of experience supporting sponsors that range from Big Pharma to small biotech, as well as CROs, and other service providers. Its four unique services—sourcing, packaging/labeling, ancillaries and patient solutions—work together to create flexibility, improve effectiveness, increase efficiency and eliminate waste. The company problem-solves and tailors solutions to the specific requirements and complexities of each trial, and sponsors and CROs benefit from the simplicity of having a single vendor that can provide an optimized, integrated clinical trial supply strategy that saves time and money. Learn more at www.myonex.com.

Contacts

Maryanne Walsh
+1 267-307-0876
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
  • George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
  • Mister Omaha Tries The Turf At Lone Star Park
  • Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
  • Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • TURRENTINE: A Family Legacy United Through Music

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 171
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • A Foundational Claim in Human Secrecy Goes Public
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity

Similar on PennZone

  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • LKPFM Corporation Canada the importance
  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us